|Bid||0.00 x 66000|
|Ask||0.00 x 112600|
|Day's range||675.00 - 690.00|
|52-week range||559.82 - 784.00|
|PE ratio (TTM)||35.92|
|Earnings date||15 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||800.00|
Mining stocks’ correlations with gold are crucial because gold is the big brother of precious metals. The movements in the remaining three precious metals—silver, platinum, and palladium—mostly depend on gold’s movements. For our correlation analysis, we’ll look at First Majestic Silver (AG), B2Gold (BTG), Royal Gold (RGLD), and Goldcorp (GG). Mining-based funds also have high correlations with precious metals.
Mining stocks tend to take their cues from gold price movement. Mining-based funds have a high correlation with precious metals. The VanEck Vectors Gold Miners ETF (GDX) and the Sprott Gold Miners (SGDM) rose 1.1% and 0.52%, respectively, on Friday, February 23.
Could Gold Catch a Bid if Equities Stay Weak in 2018? The unemployment rate for January came in at 4.1%, in-line with economists’ expectations. The jobs report from the Bureau of Labor Statistics is a very closely watched piece of data, mainly due to the repercussions jobs, wages, and unemployment data can have on the US dollar, inflation, and ultimately interest rates.
BTG plc , the global healthcare company, today highlighted OPTALYSE PE one year trial results, presented at the International Society on Endovascular Therapy in Florida. The findings confirm that bilateral pulmonary embolism patients treated in as little as 2 hours with a total tissue plasminogen activator dose as low as 8mg continue to show improvements in RV/LV ratio over the long term with a very ...
A correlation study of miners to gold is important since gold is the most crucial of all the four precious metals, and its price could be a determinant of other metals as well as mining stocks. In this part, we’ll be looking at B2Gold (BTG), Royal Gold (RGLD). Mining-based funds are also known to have a high correlation with precious metals.
What Led to the Fall in Gold and Silver? Gold prices retreated from their four-month high of $1,340 and slipped 0.81% on Wednesday, January 17. Gold futures for January expiration ended the day at $1,338 per ounce.
A U.S. administrative court invalidated a Johnson & Johnson (JNJ.N) patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc (BTG.L). The Patent Trial and Appeal Board said a Johnson & Johnson patent describing a method of administering Zytiga should not have been granted because the process it described was obvious.
** Shares in British healthcare group BTG fall more than 5% after U.S. court invalidates patent on blockbuster prostate cancer drug Zytiga from partner Johnson & Johnson ** BTG earns royalties on sales ...
A U.S. administrative court invalidated a Johnson & Johnson (NYSE: JNJ - news) patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc (Frankfurt: 908827 - news) . The Patent Trial and Appeal Board said a Johnson & Johnson patent describing a method of administering Zytiga should not have been granted because the process it described was obvious.
All four precious metals had an up day on Wednesday, December 27. Gold futures for January expiration rose 0.23% and closed at $1,287 per ounce.
A slate of U.S. tax reforms could provide a lift for European companies that sell into the country. Proposals passed by lawmakers on Wednesday will see the corporate tax rate in the United States fall to 21 percent from 35 percent, a dramatic cut that is likely to boost the profits of American corporations. The change is likely to benefit some European companies, too, and investment banks have been quick to point that out: JP Morgan has introduced a basket of 41 European stocks it believes will benefit most for its clients to buy.
BTG plc , the global specialist healthcare company, today highlights the commencement of the KNOCOUT PE study. The KNOCOUT PE study will measure how hospitals and patients are benefitting from a new standard of care in the treatment of Pulmonary Embolism utilizing EKOS® therapy with faster, and even safer protocols, proven effective in the OPTALYSE PE study.